Stephen B. Shohet Net Worth

The estimated Net Worth of Stephen B. Shohet is at least $4.02 Millón dollars as of 10 December 2018. Stephen Shohet owns over 58,557 units of Amphastar Pharmaceuticals Inc stock worth over $4,023,083 and over the last 10 years Stephen sold AMPH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stephen Shohet AMPH stock SEC Form 4 insiders trading

Stephen has made over 15 trades of the Amphastar Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Stephen exercised 58,557 units of AMPH stock worth $858,446 on 10 December 2018.

The largest trade Stephen's ever made was exercising 58,557 units of Amphastar Pharmaceuticals Inc stock on 10 December 2018 worth over $858,446. On average, Stephen trades about 11,376 units every 79 days since 2014. As of 10 December 2018 Stephen still owns at least 89,263 units of Amphastar Pharmaceuticals Inc stock.

You can see the complete history of Stephen Shohet stock trades at the bottom of the page.

What's Stephen Shohet's mailing address?

Stephen's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.

Insiders trading at Amphastar Pharmaceuticals Inc

Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins y William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.

What does Amphastar Pharmaceuticals Inc do?

amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int

Complete history of Stephen Shohet stock trades at Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc executives and stock owners

Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jack Zhang,
  President, Chief Executive Officer, Chief Scientific Officer, Director
• Mary Luo,
  Chief Operating Officer, Chief Scientist and Chairman of the Board
• Dr. Yongfeng Zhang,
  Co-founder, Pres, CEO, Chief Scientific Officer & Director
• William Peters,
  Chief Financial Officer, Senior Vice President, Treasurer and President of International Medication Systems, Limited
• Dr. Ziping Luo,
  Chairman, Chief Scientist & COO
• Rong Zhou,
  Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc.
• William J. Peters M.B.A.,
  CFO, Treasurer & Exec. VP of Fin.
• Rong Zhou,
  Exec. VP of Production Center
• Jacob Liawatidewi M.B.A.,
  Exec. VP of Corp. Admin. Center, Sales & Marketing and Corp. Sec.
• Diane Gerst,
  Director
• Richard Prins,
  Lead Independent Director
• Richard Koo,
  Independent Director
• Howard Lee,
  Independent Director
• Michael Zasloff,
  Independent Director
• Floyd Petersen,
  Independent Director
• Jacob Liawatidewi,
  Senior Vice President of Sales and Marketing, Corporate Administration Center, Corporate Secretary
• Peter Langosh,
  VP of Operational Improvement and VP of Internal Audit
• Tony Marrs,
  Sr. VP of Regulatory Affairs and Clinical Operations
• Dan Dischner,
  VP of Corp. Communications
• Stephen B. Shohet,
  Director
• Gayle Deflin,
  
• Physics & Chemistry Laborat...,
  10% owner
• Mary Z.Zhang Jack Y. Luo,
  COO,Chief Scientist & ChairmanCEO & Chief Scientific Officer
• Jason B. Shandell,
  President and General Counsel
• Marilyn J. Purchase,
  Corp. Exec. VP of Operations
• David Maris,
  Director
• Jack Y.Luo Mary Z.Applied P...,
  CEO & Chief Scientific OfficerCOO,Chief Scientist & Chairman
• Yakob Liawatidewi,
  EVP CORP ADMIN CENTER